share_log

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $64 Price Target

Benzinga ·  Dec 4, 2024 14:34

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $64 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 264

Recommended

Write a comment